2 recession-proof stocks for 2017

Could these shares be the perfect antidote to any Brexit-related anxiety?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As we creep towards 2017 and our eventual exit from the EU, it’s likely that more investors will look towards companies that offer services or products that we’ll buy whatever the weather (or economic climate). Utilities and consumer staples will inevitably garner the most attention and, if history is anything to go by, justifiably so. Nevertheless, there’s one niche market out there that I think offers a perfect blend of defensive qualities and dynamic growth, namely that which focuses on the UK’s love of pets. Let’s look at two examples of companies operating in this area, one of which reported to the market earlier today.

Resilient market

Despite the substantial drop in its share price this morning (down almost 8%), £1.15bn retailer Pets At Home‘s (LSE: PETS) interim figures aren’t bad at all. Over the last six months, like-for-like revenue across the group was up by 2.5% with food sales rising by 3.7% and accessories by 5.9%. Even more positive was the 47.6% growth in its veterinary business from £41.9m to £61.9m. 

Elsewhere, the Wilmslow-based company reported that investment in its online offering was “delivering results” and that its space rollout remains on track with eight new superstores, 17 vet practices and 18 grooming salons opening over the past year. For those who like to focus on fundamentals, Pets At Home also reported an 11.5% rise in free cashflow to £34.4m and a reduction in leverage from 1.5 times to 1.3 times. This last detail is noteworthy as it shows that the company is continuing to focus on steadily reducing its debt pile, no bad thing in an uncertain economic climate. While reflecting that the trading environment wasn’t easy, CEO Ian Kellett remarked that the company was “confident in the long-term outlook” and the “developing potential” of the aforementioned Services business.

On a forecast price-to-earnings (P/E) ratio of 15, I’d say that shares in Pets in Home are reasonably valued and, thanks to today’s 25% dividend hike, should now feature prominently on the radars of those who invest for income.

Small-cap star 

For those who prefer smaller companies, an alternative to Pets At Home might be CVS Group (LSE: CVSG). The £539m cap is the largest veterinary group in the UK and, with good reason, has attracted quite a following among those who hunt for shares at the lower end of the market spectrum. Over the last five years, its share price has rocketed 1,000% thanks to consistent growth in revenue and net profits. Only today, it’s up 12.5%.

Can this fantastic run of form continue? Quite possibly. A rise of almost 170% in earnings per share has been pencilled-in for 2017. Moreover, the company’s recent acquisition of a small animal practice based in the east of the Netherlands is intended to be the first step in the development of a similar business to that operating in the UK. One thing’s for sure, CVS isn’t standing still.

Any downsides? Well, on a forecast price-to-earnings (P/E) ratio of 24 for 2017, shares in a CVS are rather expensive and unlikely to be of interest to those who scour the market for value. Nevertheless, those with stronger appetites for risk and longer investing horizons may be tempted and given the company’s strong pipeline of acquisitions, I wouldn’t blame them.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »